CB-839

1 stories · following the connections

Business

Updated Results from Phase I Study of CB-839 in Combination with Paclitaxel in Patients with Triple Negative Breast Cancer to be Presented at the 2017 San Antonio Breast Cancer Symposium

By Nasdaq OMXDec 5, 2017, 1:00 PM UTC